RxDoctor Payments Data

Silvia Coleman, MD

Internal Medicine · New Castle, PANPI 1003807546

Payments from drug & device makers

$13,388in general payments, 2019–2025

Across 821 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$624
  • Johnson & Johnson$623
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,27699%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK98$1,489
AbbVie(2 entities)87$1,397
Pfizer98$1,339
Novo Nordisk59$1,060
Lilly USA, LLC39$624
Johnson & Johnson46$623
Amarin Pharma, Inc.40$598
Merck32$551
Amgen(2 entities)28$509
Takeda Pharmaceuticals U.S.A., Inc.29$419
Boehringer Ingelheim23$382
AstraZeneca22$377
Bayer16$295
Shield Therapeutics Inc12$211
Lundbeck LLC9$210
Sumitomo Pharma America, Inc.12$195
Novartis12$192
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$167
Biohaven Pharmaceutical Holding Company Ltd.7$161
E.r. Squibb & Sons, L.L.C.10$155
Mylan Specialty L.p.5$155
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$140
Esperion Therapeutics, Inc.7$135
Avanir Pharmaceuticals, Inc.8$124
Eisai Inc.7$123
Otsuka America Pharmaceutical, Inc.5$112
Daiichi Sankyo Inc.6$108
Abbott6$105
Axsome Therapeutics, Inc.4$87
Sunovion Pharmaceuticals Inc.5$82
Currax Pharmaceuticals LLC5$81
Xeris Pharmaceuticals, Inc.4$80
Paratek Pharmaceuticals, Inc.5$76
Exact Sciences3$65
Viatris Specialty LLC3$64
Sanofi-aventis U.S. LLC4$62
Phathom Pharmaceuticals, Inc.4$57
Strongbridge US Inc.4$56
Astellas Pharma US Inc4$55
Kowa Pharmaceuticals America, Inc.3$51
Biohaven Pharmaceuticals, Inc.2$50
Teva Pharmaceuticals USA, Inc.3$47
Biogen3$47
Idorsia Pharmaceuticals US Inc2$45
Nevro Corp.2$45
Medtronic2$45
Kaleo, Inc.3$41
Amneal Pharmaceuticals LLC2$39
IBSA Pharma Inc.2$33
Sanofi2$32
Almatica Pharma LLC2$31
Mannkind Corporation1$24
Seqirus USA Inc1$19
Appliedvr Inc1$18
Genentech USA, Inc.1$17
Dexcom, Inc.1$15
Evoke Pharma, Inc.1$15
Regeneron Healthcare Solutions, Inc.1$14
Neos Therapeutics, LP1$13
Azurity Pharmaceuticals, Inc.1$13

How this compares

$13,388 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$164,008
Medicare patients
322
Services billed
1,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin559$349,832
EliquisApixaban811$334,949
Trelegy ElliptaFluticasone/Umeclidin/Vilanter212$147,067
RybelsusSemaglutide156$144,358
FarxigaDapagliflozin Propanediol263$135,286
XareltoRivaroxaban286$133,593
JanuviaSitagliptin Phosphate203$108,057
MounjaroTirzepatide86$91,000
OzempicSemaglutide61$65,765
TrulicityDulaglutide63$64,504
Breo ElliptaFluticasone/Vilanterol122$55,726
TradjentaLinagliptin116$53,501
NuplazidPimavanserin Tartrate15$46,416
Breztri AerosphereBudesonide/Glycopyr/Formoterol67$42,994
MyrbetriqMirabegron100$40,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$382$403,333675 claims
PfizerEliquis$1,339$334,949811 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$1,489$245,912430 claims
Novo NordiskRybelsus, Ozempic$1,060$210,123217 claims
AstraZenecaFarxiga, Breztri Aerosphere$377$178,281330 claims
MerckJanuvia, Janumet Xr, Janumet$551$156,430265 claims
Lilly USA, LLCMounjaro, Trulicity$624$155,504149 claims
Johnson & JohnsonXarelto$623$133,593286 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$112$43,90439 claims
Astellas Pharma US IncMyrbetriq$55$40,961100 claims
AbbVieLinzess, Synthroid$1,397$31,140261 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$419$25,89672 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in New Castle

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →